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Estimating protein intake
in maintenance
hemodialysis patients
To the Editor: We have read with interest the paper in
a recent issue of Kidney International by Masud et al [1]
on the precision of estimating the protein intake in chronic
renal failure (CRF). The authors provide evidence that
the amount of protein intake does not reflect the excretion
of fecal nitrogen; thus, fecal nitrogen, even if correlated
with body weight, does not influence the measurement
of protein intake in stable CRF patients. The accurate
estimation of protein intake is even more crucial in hemo-
dialysis (HD) patients because of the greater risk of mal-
nutrition. In clinical practice, protein intake is usually
estimated in HD by the calculation of protein nitrogen
appearance (PNA) derived from the urea nitrogen ap-
pearance (UNA) during the interdialytic period [2]. To
note, the effect of fecal nitrogen excretion on the mea-
surement of protein intake and the influence of different
amount of eaten protein on the fecal excretion of nitro-
gen, as well, have not been previously evaluated.
We analyzed 139 series of three-day period daily pro-
tein intakes measured during the long interdialytic inter-
val. The mean interdialytic protein intake estimated by
PNA was 1.26  0.28 g/kg body weight/day (range, 0.66
to 2.18), while the daily protein intake progressively de-
creased from 1.50  0.43 to 1.32  0.35 and to 1.00 
0.34 g/kg body weight/day (P  0.001) during the three-
day period (range, 0.71 to 2.91, 0.49 to 2.29, and 0.22 to
1.82, respectively, on the 1st, 2nd, and 3rd day). Twenty-
seven patients (age, 32 to 70 years; body weight, 52 to
78 kg) collected the daily feces during the same time
period in order to measure the fecal nitrogen excretion.
At variance with UNA, which gradually dropped, fecal
nitrogen (FN) remained unchanged during the interdia-
lytic period (Fig. 1). Fecal nitrogen excretion was remark-
ably stable during the study, measuring 5.0 mg/kg body
weight/day (range, 4.0 to 6.6) on each of the 3 days (NS);
the coefficient of variation was lower than 3% (range,
0.5 to 4.0).
In HD patients, variations of eaten protein do not
affect the fecal excretion of nitrogen; therefore, in these
patients, as demonstrated in CRF [1], fecal nitrogen does
not influence the measurement of protein intake.
Fig. 1. Daily measurement of urea nitrogen appearance (UNA) ()
and fecal nitrogen excretion (FN) ( ) in chronic hemodialysis patients
during the long interdialytic period. *P  0.05 vs. 1; P  0.05 vs. 2.
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Plasma level of soluble Fas is
an independent marker of
cardiovascular disease in
ESRD patients
To the Editor: In the October 2002 issue of Kidney
International, Caglar K et al [1] discussed the potential
inflammatory role of hemodialysis (HD) in end-stage re-
nal disease (ESRD) patients. Evidence suggests that apo-
ptotic endothelial cells are present at sites of atherosclero-
sis plaques [2]. To evaluate the association between
inflammation, endothelial apoptosis, and cardiovascular
(CV) morbidity and mortality in ESRD patients, we have
measured plasma level of soluble Fas (sFas) was measured
by enzyme-linked immunosorbent assay (ELISA) in a
cross-sectional analysis [3]. Eighteen chronic HD patients,
9 non-HD ESRD patients (CrCl, 10.3 2.4 mL/min), and
15 age- and sex-matched healthy subjects (CrCl, 98.4 3.5
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Table 1. Adjusted odds ratios for cardiovascular diseases associated
with an increase of one quintile in plasma sFas and CRP
Markers Odds ratio (95% CI)a P value
sFas 1.74 (1.21–2.89) 0.01
CRP 2.08 (1.11–3.24) 0.008
Abbreviations are: CRP, C-reactive protein; sFas, soluble Fas.
aOdds ratios are adjusted for the following additional risk factors: age, sex,
traditional risk factors for atherosclerosis (obesity, hypertension, hyperlipidemia,
smoking, and diabetes), serum albumin level, nutritional status (nPCR), and dial-
ysis adequacy (eKt/V).
mL/min) were enrolled. Clinical data included duration of
ESRD, traditional risk factors for CV disease (CVD),
normalized protein catabolic rate (nPCR) in g/kg/d, and
dialysis adequacy (eKt/V). Cardiovascular morbidity and
mortality criteria were myocardial infarction, angina pec-
toris, coronary artery revascularization, a positive stress
test, or cardiac imaging procedure. Hemodialysis and non-
HD ESRD patients had evidence of CVD compared with
control patients (P  0.02) with 11%, 6%, and 0% CV
mortality, respectively (P  0.01). Levels of sFas were
significantly higher in HD patients compared with non-
HD ESRD patients (P  0.02) and control patients (P 
0.01). After adjustment for traditional CV risk factors,
sFas and C-reactive protein (CRP) remained independent
markers of CVD (Table 1). The correlation between sFas
and CRP was R2  0.67 (P 0.005). These results suggest
that sFas may represent a novel and independent predictor
of CVD morbidity and mortality in ESRD patients. The
addition of sFas to the inflammatory factor CRP allows
better determination of CVD in ESRD patients.
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Dialysate calcium use in
hemodialysis patients
To the Editor: A recent Kidney International article [1]
demonstrates an impressive decrease in cardiac calcifica-
tion with the use of sevelamer as phosphate binder when
compared to calcium-based binders. However, there is a
striking omission in the data. Dialysate calcium is not
presented at all. Dialysate calcium doubtlessly has a strong
impact on most, if not all, of the study outcomes, including
serum calcium, phosphorus, and parathyroid hormone
(PTH) [2], and most probably, soft tissue calcification.
Dialysate calcium is an important variable that should
have been measured and presented to aid in the interpre-
tation of the study.
Another omission in the data is the mean PTH level.
The median of PTH levels that is given is an extremely
limited description of this important parameter in the
study. Why was the mean  SD not presented?
The omission of easy-to-obtain, pertinent variables, ob-
scures the clinical implications of this study.
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Renal disease medications
and evidence-biased medicine
To the Editor: In a recent article in Kidney International
[1] I read about a comparison between sevelamer and cal-
cium-containing substances. Although the paper seemed
quite scientific, I feel the need to state some objections.
The paper compares three different medications in he-
modialysis patients but considers two of them to be the
same: calcium carbonate and calcium acetate. The truth
is that these two calcium-containing substances are quite
different, both in their effectiveness and their side ef-
fects. The mixed data this paper presents from the pa-
tients in the United States and Europe who used calcium
acetate and calcium carbonate, respectively, is biased.
In many European countries calcium carbonate is the
only calcium-containing phosphate binder that exists. In
the United States, calcium acetate has been used for
several years, in many cases superseding calcium carbon-
ate. The trouble with this paper is that it does not say
how many patients used calcium carbonate and how
many used calcium acetate. It only says that half the
